Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 87

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 87
---
 strain) and randomized (n=8 per
group) into three groups: Nano-Mupirocin (25 mg/kg IV BID), free mupirocin (same dose), or saline control. After 3 days of treatment,
animals were euthanized, and bacterial counts were determined in vegetations, kidneys, and spleen. Nano-Mupirocin-treated animals showed
statistically significant reductions in bacterial counts across all tissues compared to controls.

| Figure 3: Rabbit survival. Percent survival of rabbits in endocarditis study across the treatment groups. |     | Figure 4: Rabbit PK Profile. Mupirocin plasma concentrations after IV administration of 25 mg/kg Nano-mupirocin vs. free mupirocin. |

Reference: Ahuva Cern, Ayelet Michael-Gayego, Yaelle Bavli, Erez Koren, Amiram Goldblum, Allon E. Moses, Yan Q. Xiong and Yechezkel Barenholz* Nano-mupirocin: enabling the parenteral activity of mupirocin DOI 10.1515/ejnm-2016-0006

<div align='center'>53</div>

| 4. | Murine Model – Necrotizing Fasciitis (Streptococcus pyogenes) |

A dose–response study was conducted in a
mouse model of necrotizing fasciitis using group A Streptococcus (GAS). Mice (n=6 per group) received a single IV dose of Nano-Mupirocin
(1.1–57 mg/kg) one hour post-infection. Survival was monitored for 5 days. All untreated mice died within 48 hours. Complete survival
was observed at doses ≥11 mg/kg, with a clear dose-dependent protection from mortality and clinical symptoms.

| Figure 5. Dose                                                                                                                   
 response to Nano-Mupirocin in a murine necrotizing fasciitis model.                                                              
 Figure 6: Mortality                                                                                                              
 during the study and disease parameters (rough hair and wound development) 48 h after the bacterial challenge. (A) A study to    
 compare one prophylactic dose of Nano-Mupirocin (50 mg/kg) vs. free mupirocin administered prophylactically and 3 and 24 h after 
 the bacterial challenge. (B) A prophylactic dose response study. (C) Nano-Mupiro